RNS out.15 Mar 2021 07:11
Operational and financial highlights
· Successful combined and formulated blend of probiotic food supplement, AxisBiotix-Ps™, by partner Winclove, completed ahead of schedule
o Post-period end: commencement of supplement consumer study with strong initial data from over 150 participants reporting at the 14 day timepoint
· SkinBiotix programme with Croda progressing to plan; current focus is scaling-up manufacture of lysate to higher (commercial) volumes; commercialisation on track for 2022
· Placing and open offer in October completed, raising £4.45m (gross)
· Cash as at 31 December 2020 £5.5m (2019: £2.5m)